Bergenbio Asa Stock Performance

BRRGF Stock  USD 97.09  97.08  1,000,828%   
BerGenBio ASA holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -52777.68, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning BerGenBio ASA are expected to decrease by larger amounts. On the other hand, during market turmoil, BerGenBio ASA is expected to outperform it. Use BerGenBio ASA information ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to analyze future returns on BerGenBio ASA.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in BerGenBio ASA are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, BerGenBio ASA reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow721.6 M
Total Cashflows From Investing Activities3.1 M
  

BerGenBio ASA Relative Risk vs. Return Landscape

If you would invest  9,709  in BerGenBio ASA on October 28, 2025 and sell it today you would earn a total of  0.00  from holding BerGenBio ASA or generate 0.0% return on investment over 90 days. BerGenBio ASA is currently producing 28.5874% returns and takes up 178.1768% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than BerGenBio, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon BerGenBio ASA is expected to generate 241.63 times more return on investment than the market. However, the company is 241.63 times more volatile than its market benchmark. It trades about 0.16 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

BerGenBio ASA Target Price Odds to finish over Current Price

The tendency of BerGenBio Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 97.09 90 days 97.09 
about 43.03
Based on a normal probability distribution, the odds of BerGenBio ASA to move above the current price in 90 days from now is about 43.03 (This BerGenBio ASA probability density function shows the probability of BerGenBio Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon BerGenBio ASA has a beta of -52777.68 suggesting as returns on its benchmark rise, returns on holding BerGenBio ASA are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, BerGenBio ASA is expected to outperform its benchmark. In addition to that BerGenBio ASA has an alpha of 18918.4328, implying that it can generate a 18918.43 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   BerGenBio ASA Price Density   
       Price  

Predictive Modules for BerGenBio ASA

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BerGenBio ASA. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
4.8597.099,806
Details
Intrinsic
Valuation
LowRealHigh
3.0260.449,769
Details
Naive
Forecast
LowNextHigh
1.8492.16270.33
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
35.6489.04142.44
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as BerGenBio ASA. Your research has to be compared to or analyzed against BerGenBio ASA's peers to derive any actionable benefits. When done correctly, BerGenBio ASA's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in BerGenBio ASA.

BerGenBio ASA Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. BerGenBio ASA is not an exception. The market had few large corrections towards the BerGenBio ASA's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BerGenBio ASA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BerGenBio ASA within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
18,918
β
Beta against Dow Jones-52,778
σ
Overall volatility
16.69
Ir
Information ratio 0.12

BerGenBio ASA Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BerGenBio ASA for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BerGenBio ASA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
BerGenBio ASA is way too risky over 90 days horizon
BerGenBio ASA appears to be risky and price may revert if volatility continues
BerGenBio ASA has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 774 K. Net Loss for the year was (309.36 M) with profit before overhead, payroll, taxes, and interest of 774 K.
BerGenBio ASA has accumulated about 509.41 M in cash with (303.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.77.
Roughly 35.0% of the company shares are held by company insiders

BerGenBio ASA Fundamentals Growth

BerGenBio Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BerGenBio ASA, and BerGenBio ASA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BerGenBio Pink Sheet performance.

About BerGenBio ASA Performance

By analyzing BerGenBio ASA's fundamental ratios, stakeholders can gain valuable insights into BerGenBio ASA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BerGenBio ASA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BerGenBio ASA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. The company was incorporated in 2007 and is headquartered in Bergen, Norway. Bergenbio is traded on OTC Exchange in the United States.

Things to note about BerGenBio ASA performance evaluation

Checking the ongoing alerts about BerGenBio ASA for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BerGenBio ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
BerGenBio ASA is way too risky over 90 days horizon
BerGenBio ASA appears to be risky and price may revert if volatility continues
BerGenBio ASA has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 774 K. Net Loss for the year was (309.36 M) with profit before overhead, payroll, taxes, and interest of 774 K.
BerGenBio ASA has accumulated about 509.41 M in cash with (303.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.77.
Roughly 35.0% of the company shares are held by company insiders
Evaluating BerGenBio ASA's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate BerGenBio ASA's pink sheet performance include:
  • Analyzing BerGenBio ASA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BerGenBio ASA's stock is overvalued or undervalued compared to its peers.
  • Examining BerGenBio ASA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating BerGenBio ASA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BerGenBio ASA's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of BerGenBio ASA's pink sheet. These opinions can provide insight into BerGenBio ASA's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating BerGenBio ASA's pink sheet performance is not an exact science, and many factors can impact BerGenBio ASA's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for BerGenBio Pink Sheet analysis

When running BerGenBio ASA's price analysis, check to measure BerGenBio ASA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BerGenBio ASA is operating at the current time. Most of BerGenBio ASA's value examination focuses on studying past and present price action to predict the probability of BerGenBio ASA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BerGenBio ASA's price. Additionally, you may evaluate how the addition of BerGenBio ASA to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance